TPOXX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tpoxx, and when can generic versions of Tpoxx launch?
Tpoxx is a drug marketed by Siga Technologies and is included in one NDA. There are six patents protecting this drug.
This drug has seventy patent family members in twenty-one countries.
The generic ingredient in TPOXX is tecovirimat. One supplier is listed for this compound. Additional details are available on the tecovirimat profile page.
DrugPatentWatch® Generic Entry Outlook for Tpoxx
Tpoxx will be eligible for patent challenges on July 13, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 23, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TPOXX
International Patents: | 70 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 23 |
Patent Applications: | 76 |
What excipients (inactive ingredients) are in TPOXX? | TPOXX excipients list |
DailyMed Link: | TPOXX at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for TPOXX
Generic Entry Date for TPOXX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for TPOXX
US Patents and Regulatory Information for TPOXX
TPOXX is protected by six US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TPOXX is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TPOXX
Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
Polymorphic forms of ST-246 and methods of preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting TPOXX
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TPOXX
When does loss-of-exclusivity occur for TPOXX?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 21
Estimated Expiration: See Plans and Pricing
Argentina
Patent: 3435
Estimated Expiration: See Plans and Pricing
Australia
Patent: 11232551
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 2012023743
Estimated Expiration: See Plans and Pricing
Canada
Patent: 93533
Estimated Expiration: See Plans and Pricing
Patent: 30671
Estimated Expiration: See Plans and Pricing
Chile
Patent: 12002621
Estimated Expiration: See Plans and Pricing
China
Patent: 3068232
Estimated Expiration: See Plans and Pricing
Patent: 5111130
Estimated Expiration: See Plans and Pricing
Patent: 5111131
Estimated Expiration: See Plans and Pricing
Patent: 5175311
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 49871
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 49871
Estimated Expiration: See Plans and Pricing
Israel
Patent: 1991
Estimated Expiration: See Plans and Pricing
Patent: 1730
Estimated Expiration: See Plans and Pricing
Patent: 1731
Estimated Expiration: See Plans and Pricing
Patent: 8239
Estimated Expiration: See Plans and Pricing
Japan
Patent: 18041
Estimated Expiration: See Plans and Pricing
Patent: 13522371
Estimated Expiration: See Plans and Pricing
Patent: 16040323
Estimated Expiration: See Plans and Pricing
Patent: 18012735
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 1428
Estimated Expiration: See Plans and Pricing
Patent: 12010859
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 2578
Estimated Expiration: See Plans and Pricing
Peru
Patent: 130212
Estimated Expiration: See Plans and Pricing
Patent: 170944
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 78606
Estimated Expiration: See Plans and Pricing
Patent: 12144818
Estimated Expiration: See Plans and Pricing
Patent: 15146899
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 4201
Estimated Expiration: See Plans and Pricing
Patent: 201501936P
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1207141
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 130018271
Estimated Expiration: See Plans and Pricing
Patent: 150011016
Estimated Expiration: See Plans and Pricing
Patent: 150092354
Estimated Expiration: See Plans and Pricing
Patent: 160028489
Estimated Expiration: See Plans and Pricing
Patent: 160062208
Estimated Expiration: See Plans and Pricing
Patent: 170102070
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TPOXX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 2012010859 | FORMAS POLIMORFICAS ST-246 Y METODOS DE PREPARACION. (POLYMORPHIC FORMS ST-246 AND METHODS OF PREPARATION.) | See Plans and Pricing |
Spain | 2632313 | See Plans and Pricing | |
South Korea | 20170102070 | 다형체 형태 ST―246 및 제조방법 (POLYMORPHIC FORMS ST-246 AND METHODS OF PREPARATION) | See Plans and Pricing |
Denmark | 1638938 | See Plans and Pricing | |
European Patent Office | 3006425 | COMPOSITION PHARMACEUTIQUE DESTINEES AU TRAITEMENT ET A LA PRÉVENTION D'UNE INFECTION CAUSÉE PAR DES ORTHOPOXVIRUS (PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES) | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |